Page 39 - Institut Pasteur News Today

In this interview, NewsMedical speaks with Professor Serge Mostowy and Sydney Miles about their research on bacterial infection, and, in particular, on Shigella Flexneri and enteropathogens.

Antibiotic treatment disrupts the balance of beneficial and harmful bacteria in a person's gut. That disruption can lead to the overgrowth of fungal species in the gut mycobiota, including the common intestinal yeast Candida albicans.

Designation follows recent FDA award of Rare Pediatric Disease Designation to Sensorion for OTOF-GT program Sensorion is on track to file a CTA for OTOF-GT in H1 2023 Regulatory News:

Over 30 vets in Algiers from  various veterinary agencies took part to reproductive surgery training from Mayhew’s 'Dr. Mo'.

Jakob Ruess, a researcher in Mathematics Applied to Biology and member of the InBio project team, has recently been awarded a European ERC Starting Grant. Over the next five years, through his BridgingScales project, he will now be able to explore a new approach to the mathematical modelling of cellular processes.

Catherine Lucey, MD, a key campus leader who has been instrumental in UCSF’s success over the past decade, has been named executive vice chancellor and provost, beginning in January of 2023.

"...the Black Death was an important selective pressure to the evolution of the human immune system."

Regulatory News: Sensorion (FR0012596468 ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent

Microbiome clinical trial pipeline constitutes 130+ key companies continuously working towards developing 200+ microbiome drugs, analyzes DelveInsight LAS VEGAS, Nov. 9, 2022 /PRNewswire/

/PRNewswire/ -- DelveInsights Microbiome Competitive Landscape – 2022 report provides comprehensive global coverage of available, marketed, and pipeline...